Acrivon is a clinical-stage biopharmaceutical company that discovers and develops precision cancer medicines using its proprietary Generative Phosphoproteomics (AP3) platform, which measures drug-induced changes in protein signaling pathways in tumor cells to identify treatment-responsive patients and resistance mechanisms. The company's lead program, ACR-368, is a CHK1/2 inhibitor supported by OncoSignature, a companion diagnostic test that uses proteomics to predict individual patient response; Acrivon also develops internal pipeline programs targeting other cancer-driving pathways. The company will generate revenue from future drug approvals and sales through royalties and milestone payments, while also providing proprietary diagnostic testing services to oncology patients and physicians seeking to optimize treatment selection where traditional genetic approaches have proven insufficient.